Intervention Review

You have free access to this content

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease

  1. Esther J van Zuuren1,*,
  2. Zbys Fedorowicz2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 12 JUN 2013

Assessed as up-to-date: 5 JUN 2013

DOI: 10.1002/14651858.CD010155.pub2


How to Cite

van Zuuren EJ, Fedorowicz Z. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010155. DOI: 10.1002/14651858.CD010155.pub2.

Author Information

  1. 1

    Leiden University Medical Center, Department of Dermatology, Leiden, Netherlands

  2. 2

    The Cochrane Collaboration, UKCC (Bahrain Branch), Awali, Bahrain

*Esther J van Zuuren, Department of Dermatology, Leiden University Medical Center, PO Box 9600, B1-Q, Leiden, 2300 RC, Netherlands. E.J.van_Zuuren@lumc.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 12 JUN 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Tinzaparin versus placebo, Outcome 1 Duration of the pain.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Tinzaparin versus placebo, Outcome 2 Number of hospitalisations days.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Tinzaparin versus placebo, Outcome 3 Number of adverse events.